Learn / Epidemiology / Evaluating interventions
The randomised controlled trial
14 minute read · 6-question quiz
What you will learn
Describe the essential features of a randomised controlled trial and why each protects against bias
Distinguish randomisation, allocation concealment and blinding
Describe the phases of clinical development and the CONSORT flow
The randomised controlled trial (RCT) is the benchmark for judging an intervention. Participants are allocated by chance to the intervention or a comparison (placebo, standard care), then followed for the outcome. Because chance decides allocation, groups are alike on all characteristics, measured and unmeasured, apart from the intervention, so differences in outcome can be attributed to it.
The ingredients of a good trial
| Feature | Purpose | Notes |
| Clear question (PICO) | Population, Intervention, Comparator, Outcome | One primary outcome |
| Eligibility criteria | Define who is studied | Trade-off between internal validity and generalisability |
| Randomisation | Creates comparable groups | Computer-generated sequence; blocks and stratification balance size and key factors |
| Allocation concealment | Prevents recruiters from foreseeing the next assignment | Central telephone/web system, sealed opaque envelopes. Different from blinding. |
| Blinding (masking) | Prevents knowledge of allocation changing behaviour or assessment | Single, double, triple; placebo or sham |
| Sample size | Power to detect the minimal important effect | Chapter 9 of biostatistics |
| Follow-up and ITT analysis | Preserve randomisation | Chapter 10 of biostatistics |
| Registration and protocol | Prevent selective reporting | ClinicalTrials.gov, PACTR, ISRCTN |
| Ethics approval and consent | Protect participants | Declaration of Helsinki, ICH-GCP, national ethics committees (in Uganda: a REC plus the UNCST registration) |
Types of randomisation
- Simple: like tossing a coin; fine for large trials but can leave unequal groups in small ones.
- Block: randomise within blocks of, say, 4 or 6, so group sizes stay balanced throughout.
- Stratified: separate sequences within strata of key prognostic factors (site, sex).
- Minimisation: a deterministic method that balances several factors in small trials.
Phases of clinical development
| Phase | Typical size | Main aim |
| I | 20 to 100 (often healthy volunteers) | Safety, dose, pharmacokinetics |
| II | 100 to 300 | Early efficacy and side effects; dose selection |
| III | 300 to thousands | Confirm efficacy and safety against standard care; basis for licensing |
| IV (post-marketing) | Thousands | Long-term and rare safety; real-world effectiveness |
Strengths and limitations of RCTs
Strengths: control of confounding, a causal interpretation, a framework for blinded assessment. Limitations: cost; ethical limits (cannot randomise harmful exposures); strict eligibility limits generalisation; short follow-up; hard to blind complex interventions; unsuitable for rare outcomes unless very large.
Summary
Random allocation creates comparable groups and supports causal inference.
Randomisation, allocation concealment and blinding are distinct protections.
Phases I to IV move from safety to confirmation to post-marketing surveillance.
Register trials, obtain ethical approval, pre-specify the primary outcome and analyse by intention to treat.
RCTs have limits: cost, ethics, generalisability and feasibility.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.